An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ducray, François ^a,d,h,i   de Reyniès, Aurélien ^b   Chinot, Olivier ^c,h   Idbaih, Ahmed ^d,h   Figarella Branger, Dominique ^e,h   Colin, Carole ^e,h   Karayan Tapon, Lucie ^d,h   Chneiweiss, Hervé ^f,h   Wager, Michel ^d,h   Vallette, François ^a,h   Marie, Yannick ^d,h   Rickman, David ^b   Thomas, Emilie ^b   Delattre, Jean Yves ^d,h   Honnorat, Jérôme ^a,h   Sanson, Marc ^d,h   Berger, François ^g,h  

^a INSERM   (France)

^b Laboratoire CRIS   (France)

^c Programme Cartes d'Identite des Tumeurs   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ DE POITIERS   (France)

^g UNIVERSITÉ DE NANTES   (France)

^h GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

ⁱ TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALPHA SYNUCLEIN; CARMUSTINE; CD74 ANTIGEN; COLLAGEN TYPE 8; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN E; CYCLIN E2; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 10; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRILLIN 2; HEAT SHOCK PROTEIN 70; HEPARANASE; HLA DQB1 ANTIGEN; INTERLEUKIN 8; MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STROMAL CELL DERIVED FACTOR 1; SYNTROPHIN; SYNTROPHIN GAMMA 1; TEMOZOLOMIDE; TOLL LIKE RECEPTOR 7; TRANSMEMBRANE PROTEIN 144; TRANSMEMBRANE PROTEIN 98; UNCLASSIFIED DRUG; VASCULOTROPIN A; ALKYLATING AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE LOSS; GENETIC ASSOCIATION; GENOME; GLIOBLASTOMA; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; TRANSCRIPTOMICS; UPREGULATION; DNA MICROARRAY; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES;

EID: 77956474812     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-234     Document Type: Article

References (44)

1. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Marie Mastrogianakis G, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 23;455(7216):1061-8. Epub 2008 Sep 4.
2. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science 2008, 321(5897):1807-1812. 10.1126/science.1164382, 2820389, 18772396.
3. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008, 7:41. 10.1186/1476-4598-7-41, 2415112, 18492260.
4. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64:6503-6510. 10.1158/0008-5472.CAN-04-0452, 15374961.
5. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V, Mosseri V, Hoang-Xuan K, Kujas M, Brito I, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008, 122:1778-1786. 10.1002/ijc.23270, 18076069.
6. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005, 102:5814-5819. 10.1073/pnas.0402870102, 556127, 15827123.
7. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63:1602-1607.
8. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173. 10.1016/j.ccr.2006.02.019, 16530701.
9. Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007, 13:7341-7356. 10.1158/1078-0432.CCR-06-2789, 18094416.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. 10.1016/j.ccr.2009.12.020, 20129251.
11. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005, 65:11335-11344. 10.1158/0008-5472.CAN-05-1886, 16357140.
12. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008, 26:3015-3024. 10.1200/JCO.2007.15.7164, 18565887.
13. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
14. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
15. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
16. Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007, 83:173-179. 10.1007/s11060-006-9320-0, 17219056.
17. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15. 10.1093/nar/gng015, 150247, 12582260.
18. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52. 10.1002/hep.21467, 17187432.
19. Rouveirol C, Stransky N, Hupe P, Rosa PL, Viara E, Barillot E, Radvanyi F. Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics 2006, 22:849-856. 10.1093/bioinformatics/btl004, 16434445.
20. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006, 106:2218-2223. 10.1002/cncr.21819, 16568472.
21. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005, 65:1678-1686. 10.1158/0008-5472.CAN-04-2921, 15753362.
22. Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 2006, 18:631-636. 10.1097/01.cco.0000245321.34658.f4, 16988586.
23. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007, 99:1544-1550. 10.1093/jnci/djm170, 17925535.
24. Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J, Chiocca EA. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol 2010, 12:320-327.
25. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276. 10.1093/jnci/93.4.266, 11181773.
26. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006, 1:97-117. 10.1146/annurev.pathol.1.110304.100043, 18039109.
27. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
28. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47. 10.1371/journal.pmed.0030047, 1334226,1334226, 16417408.
29. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival. Clin Cancer Res 2008, 14:2623-2630. 10.1158/1078-0432.CCR-07-4995, 18451225.
30. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004, 10:8177-8184. 10.1158/1078-0432.CCR-04-1081, 15623592.
31. Simon JM, Noel G, Chiras J, Hoang-Xuan K, Delattre JY, Baillet F, Mazeron JJ. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol 2003, 67:45-51. 10.1016/S0167-8140(03)00007-0, 12758239.
32. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848. 10.1038/359845a0, 1279432.
33. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845. 10.1038/359843a0, 1279431.
34. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622. 10.1038/nrn2175, 17643088.
35. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007, 25:4033-4042. 10.1200/JCO.2007.11.3985, 2686120, 17827451.
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.
37. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67. 10.1186/1476-4598-5-67, 1697823, 17140455.
38. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860. 10.1002/glia.20414, 16981197.
39. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235. 10.1016/j.stem.2009.01.007, 19265662.
40. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453. 10.2353/ajpath.2007.070011, 1854940, 17456751.
41. Wemmert S, Ketter R, Rahnenfuhrer J, Beerenwinkel N, Strowitzki M, Feiden W, Hartmann C, Lengauer T, Stockhammer F, Zang KD, et al. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 2005, 7:883-893. 10.1593/neo.05307, 1502025, 16242071.
42. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 2001, 19:359-365.
43. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K, Kurisu K, Goldman CK, Curiel DT, Saijo N. Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer 1998, 77:47-54. 10.1002/(SICI)1097-0215(19980703)77:1<47::AID-IJC9>3.0.CO;2-#, 9639393.
44. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 1998, 79:640-644. 10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.CO;2-Z, 9842975.